Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 39 of the 75 sources its claims cite were checked for support.

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Open access

Published version of a preprint

Abstract

The efficacy of molecularly targeted therapies may be limited by co-occurring mutations within a tumor. Conversely, these alterations may confer collateral vulnerabilities that can be therapeutically leveraged. KRAS -mutant lung cancers are distinguished by recurrent loss of the tumor suppressor STK11/ LKB1. Whether LKB1 modulates cellular responses to therapeutic stress seems unknown. Here we show that in LKB1-deficient KRAS -mutant lung cancer cells, inhibition of KRAS or its downstream effector MEK leads to hyperactivation of JNK due to loss of NUAK-mediated PP1B phosphatase activity. JNK-mediated inhibitory phosphorylation of BCL-XL rewires apoptotic dependencies, rendering LKB1-deficient cells vulnerable to MCL-1 inhibition. These results uncover an unknown role for LKB1 in regulating stress signaling and mitochondrial apoptosis independent of its tumor suppressor activity mediated by AMPK and SIK. Additionally, our study reveals a therapy-induced vulnerability in LKB1-deficient KRAS- mutant lung cancers that could be exploited as a genotype-informed strategy to improve the efficacy of KRAS-targeted therapies.

Overview

CoChat Summary

TL;DR

In LKB1-deficient KRAS-mutant lung cancer cells, KRAS or MEK inhibition hyperactivates JNK because LKB1-NUAK signaling normally maintains PP1B phosphatase activity. JNK-mediated BCL-XL phosphorylation rewires apoptotic dependencies toward MCL-1, creating a genotype-informed vulnerability to combined KRAS/MEK + MCL-1 inhibition.

Key findings

  • LKB1 loss sensitized KRAS-mutant NSCLC cells to MAPK + MCL-1 inhibition: LKB1-deficient lines showed greater ΔAUC for sotorasib + AMG 176 (*p* = 0.029) and trametinib + AMG 176 (*p* = 0.032), with robust apoptosis versus minimal apoptosis in LKB1 WT lines.
  • Phosphoproteomics quantified 27,364 unique phosphosites and identified JNK1 as the only kinase signature enriched in trametinib-treated LKB1-deficient cells relative to WT but not in kinase-dead LKB1K87I cells.
  • LKB1 suppresses JNK via NUAK1/2 and PP1B: NUAK1/2 knockdown restored drug-induced JNK phosphorylation and sensitivity, and PP1B knockdown increased pJNK and MAPK + MCL-1 inhibitor sensitivity.
  • JNK phosphorylates BCL-XL at S62; BCL-XL S62A reduced sensitivity to sotorasib or trametinib + AMG 176 (*p* = 0.000001), while S62E increased sensitivity in LKB1-restored cells, consistent with reduced BIM sequestration by BCL-XL and increased MCL-1 dependence.
  • In patient tumors and PDX models, STK11/LKB1-mutant tumors showed increased MCL-1-dependent priming after sotorasib or trametinib (*p* = 0.0002 for PDX), and sotorasib + AMG 176 improved tumor response and progression-free survival (p* = 0.00001; PFS p* = 0.0001).

Methods

  • Preclinical study using KRAS-mutant NSCLC cell lines, isogenic LKB1 re-expression/knockout models, patient tumor explants, and PDX/xenograft mouse models.
  • Main assays included CellTiter-Glo viability, annexin/PI apoptosis, western blot, co-immunoprecipitation, immunofluorescence/IHC, BH3 profiling, and mass spectrometry-based phosphoproteomics/proteomics.
  • Analyses included ΔAUC for drug combinations, synergy testing by BIGL, phosphosite signature analysis, and statistical testing with t tests, one-way/two-way ANOVA, and mixed-effects models as specified in figure legends.

Limitations

  • The paper states that the initial cell line cohort was limited and that heterogeneity was observed across cell lines; it also notes that future studies are needed to determine whether JNK phosphorylation of MCL-1 confers vulnerabilities in other therapeutic contexts.
  • The paper states that no statistical method was used to predetermine sample size, no data were excluded, and investigators were not blinded to allocation during experiments and outcome assessment.
  • Evident from the text: phosphoproteomic samples were analyzed as single biological replicates, and the clinical validation relies on a small patient sample and preclinical PDX/xenograft models rather than a prospective clinical trial.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-025-58753-y

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 LKB1 loss confers sensitivity to combined MAPK + MCL-1 inhibition in KRAS-mutant NSCLC models. A Schema for testing sotorasib drug combinations. B Relative increased efficacy of sotorasib + AMG 176 combination compared to sotorasib alone (ΔAUC—see Fig. S2A for explanation) against KRASG12C-mutant NSCLC cell lines. Each dot represents an independent biological replicate, N = 4). Comparison of ΔAUC between KRAS-mutant NSCLC cell lines stratified according to LKB1 status. *p = 0.029 (C), *p = 0.032 (D), unpaired-nonparametric t test, 2-sided. KRAS-mutant NSCLC cell lines were treated with 0.1 µM of trametinib or 1 µM of sotorasib in combination with 1 µM of AMG 176 for up to 72 h and apoptosis was assessed by annexin positivity by flow cytometry (E, data are mean and S.E.M. of N = 3 biological replicates) or live-cell imaging (F, data are mean and S.E.M. of 3 technical replicates). For annexin positivity, percentage of apoptotic cells in vehicle group was used as a control and normalized to 0. Source data are provided as a Source Data file.
Fig. 1 LKB1 loss confers sensitivity to combined MAPK + MCL-1 inhibition in KRAS-mutant NSCLC models. A Schema for testing sotorasib drug combinations. B Relative increased efficacy of sotorasib + AMG 176 combination compared to sotorasib alone (ΔAUC—see Fig. S2A for explanation) against KRASG12C-mutant NSCLC cell lines. Each dot represents an independent biological replicate, N = 4). Comparison of ΔAUC between KRAS-mutant NSCLC cell lines stratified according to LKB1 status. *p = 0.029 (C), *p = 0.032 (D), unpaired-nonparametric t test, 2-sided. KRAS-mutant NSCLC cell lines were treated with 0.1 µM of trametinib or 1 µM of sotorasib in combination with 1 µM of AMG 176 for up to 72 h and apoptosis was assessed by annexin positivity by flow cytometry (E, data are mean and S.E.M. of N = 3 biological replicates) or live-cell imaging (F, data are mean and S.E.M. of 3 technical replicates). For annexin positivity, percentage of apoptotic cells in vehicle group was used as a control and normalized to 0. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Modulating LKB1 status alters sensitivity to MAPK + MCL-1 inhibition in vitro and in vivo. A, B Comparison of relative ∆AUC for isogenic LKB1-proficient and deficient KRAS-mutant cell line pairs (EV—empty vector, LKB1—LKB1 expression vector, sgGFP or LKB1—CRISPR KO of GFP or LKB1). Each dot represents an independent biological replicate (N = 3-6). For Sotorasib, H2030: **p = 0.002, H2122: *p = 0.012, MGH1112-1: *p = 0.014, MGH1114-1: *p = 0.037, H358: **p = 0.007. For Trametinib, H2030: **p = 0.003, H2122: *p = 0.026, H23: **p = 0.002, A549: *p = 0.007, MGH1114-1: *p = 0.011, MGH1112-1: *p = 0.015, H358: **p = 0.0014, H441: ***p = 0.0005, SW1573: **p = 0.002. Paired-parametric t test, 2-sided. Apoptotic response of isogenic KRAS-mutant NSCLC cell lines after treatment with 0.1 µM trametinib or 1 µM sotorasib in combination with 1 µM of AMG 176 (annexin positivity assessed by flow cytometry (C) or live-cell imaging (D). C Each dot represents an independent biological replicate, N = 3-5, H23: **p = 0.003, MGH1112: *p = 0.015, H2030: **p = 0.0017, MGH9019-2: *p = 0.011, SW1573: ****p = 0.00001, H358: ****p = 0.000015, unpaired-nonparametric t test, two-sided. D data are mean and S.E.M. of 3 technical replicates. E Subcutaneous xenograft tumors were established from H2030 EV and H2030 LKB1 cell lines, and mice were treated with vehicle, sotorasib (30 mg/kg daily), trametinib (3 mg/kg daily), AMG 176 (50 mg/kg daily) or combination. Data shown are mean and S.E.M of N = 5-6 mice per arm, statistical difference between single agent and combination arms was determined using mixed 2-way ANOVA effects model, *p = 0.01, **p = 0.0084. Source data are provided as a Source Data file.
Fig. 2 Modulating LKB1 status alters sensitivity to MAPK + MCL-1 inhibition in vitro and in vivo. A, B Comparison of relative ∆AUC for isogenic LKB1-proficient and deficient KRAS-mutant cell line pairs (EV—empty vector, LKB1—LKB1 expression vector, sgGFP or LKB1—CRISPR KO of GFP or LKB1). Each dot represents an independent biological replicate (N = 3-6). For Sotorasib, H2030: **p = 0.002, H2122: *p = 0.012, MGH1112-1: *p = 0.014, MGH1114-1: *p = 0.037, H358: **p = 0.007. For Trametinib, H2030: **p = 0.003, H2122: *p = 0.026, H23: **p = 0.002, A549: *p = 0.007, MGH1114-1: *p = 0.011, MGH1112-1: *p = 0.015, H358: **p = 0.0014, H441: ***p = 0.0005, SW1573: **p = 0.002. Paired-parametric t test, 2-sided. Apoptotic response of isogenic KRAS-mutant NSCLC cell lines after treatment with 0.1 µM trametinib or 1 µM sotorasib in combination with 1 µM of AMG 176 (annexin positivity assessed by flow cytometry (C) or live-cell imaging (D). C Each dot represents an independent biological replicate, N = 3-5, H23: **p = 0.003, MGH1112: *p = 0.015, H2030: **p = 0.0017, MGH9019-2: *p = 0.011, SW1573: ****p = 0.00001, H358: ****p = 0.000015, unpaired-nonparametric t test, two-sided. D data are mean and S.E.M. of 3 technical replicates. E Subcutaneous xenograft tumors were established from H2030 EV and H2030 LKB1 cell lines, and mice were treated with vehicle, sotorasib (30 mg/kg daily), trametinib (3 mg/kg daily), AMG 176 (50 mg/kg daily) or combination. Data shown are mean and S.E.M of N = 5-6 mice per arm, statistical difference between single agent and combination arms was determined using mixed 2-way ANOVA effects model, *p = 0.01, **p = 0.0084. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 JNK activation in LKB1-deficient cells underlies dependency on MCL-1. A Phosphoproteomic analysis of isogenic KRAS-mutant NSCLC cell lines treated with 0.1 µM of trametinib for 48 h. B Left: Differential enrichment of phosphopeptide signatures in trametinib-treated isogenic cell line pairs. NES – normalized enrichment scores. Right, individual phospho-sites of JNK1 downstream substrates are annotated. C Change in phospho-JNK in response to MAPK + MCL-1 inhibition in isogenic H2030 and H358 cells (data are mean and S.E.M., each dot represents an independent biological replicate, N = 3-4, H2030: **p = 0.0031, H358: ***p = 0.0008, ***p = 0.0009, paired-parametric t test, 2-sided). D Change in cell number of H2030 EV cells with siJNK1 + 2 or negative control (siNC) after treatment with 0.1 µM trametinib or 1 µM sotorasib in combination with 1 µM AMG 176 quantified by live-cell imaging. Data are mean and S.E.M. of 3 technical replicates. E H2030 EV or LKB1 cells were transfected with siRNAs targeting JNK1 and 2 or siNC and then treated with sotorasib (S) or trametinib (T) ± AMG 176 (A) and viability was determined after 3 days. Each dot represents an independent biological replicate (N = 3, TA: *p = 0.017, SA: *p = 0.028, unpaired-parametric t test, two-sided). F Schematic of siRNA knockdown of LKB1 effectors in H2030 LKB1 cells. G H2030 EV or LKB1 cells transfected with corresponding siRNAs were treated with sotorasib or trametinib in the absence or presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot represents an independent biological replicate (N = 3, ****p = 0.00001, unpaired-parametric t test, 2-sided). H, I Cells were transfected with the indicated siRNAs and then treated with trametinib (0.1 µM) or sotorasib (1 µM) for 48 h, AMG 176 for 4 h or trametinib (0.1 µM) or sotorasib (1 µM) for 48 h followed by AMG 176 for 4 h. J siPP1B restores sensitivity (∆AUC) to combined sotorasib or trametinib + AMG 176. Each dot represents an independent biological replicate (N = 3, ****p = 0.00001, 2-way ANOVA). K HA-tagged WT NUAK1 (WT) or GKKK NUAK were over-expressed in H2030 isogenic cells and the interaction of NUAK1 and PP1B was assessed by Co-IP. Source data are provided as a Source Data file.
Fig. 3 JNK activation in LKB1-deficient cells underlies dependency on MCL-1. A Phosphoproteomic analysis of isogenic KRAS-mutant NSCLC cell lines treated with 0.1 µM of trametinib for 48 h. B Left: Differential enrichment of phosphopeptide signatures in trametinib-treated isogenic cell line pairs. NES – normalized enrichment scores. Right, individual phospho-sites of JNK1 downstream substrates are annotated. C Change in phospho-JNK in response to MAPK + MCL-1 inhibition in isogenic H2030 and H358 cells (data are mean and S.E.M., each dot represents an independent biological replicate, N = 3-4, H2030: **p = 0.0031, H358: ***p = 0.0008, ***p = 0.0009, paired-parametric t test, 2-sided). D Change in cell number of H2030 EV cells with siJNK1 + 2 or negative control (siNC) after treatment with 0.1 µM trametinib or 1 µM sotorasib in combination with 1 µM AMG 176 quantified by live-cell imaging. Data are mean and S.E.M. of 3 technical replicates. E H2030 EV or LKB1 cells were transfected with siRNAs targeting JNK1 and 2 or siNC and then treated with sotorasib (S) or trametinib (T) ± AMG 176 (A) and viability was determined after 3 days. Each dot represents an independent biological replicate (N = 3, TA: *p = 0.017, SA: *p = 0.028, unpaired-parametric t test, two-sided). F Schematic of siRNA knockdown of LKB1 effectors in H2030 LKB1 cells. G H2030 EV or LKB1 cells transfected with corresponding siRNAs were treated with sotorasib or trametinib in the absence or presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot represents an independent biological replicate (N = 3, ****p = 0.00001, unpaired-parametric t test, 2-sided). H, I Cells were transfected with the indicated siRNAs and then treated with trametinib (0.1 µM) or sotorasib (1 µM) for 48 h, AMG 176 for 4 h or trametinib (0.1 µM) or sotorasib (1 µM) for 48 h followed by AMG 176 for 4 h. J siPP1B restores sensitivity (∆AUC) to combined sotorasib or trametinib + AMG 176. Each dot represents an independent biological replicate (N = 3, ****p = 0.00001, 2-way ANOVA). K HA-tagged WT NUAK1 (WT) or GKKK NUAK were over-expressed in H2030 isogenic cells and the interaction of NUAK1 and PP1B was assessed by Co-IP. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 JNK phosphorylates BCL-XL to drive an MCL-1 dependent state. A Co-IP of BIM bound to MCL-1 in H2030 EV (empty vector) and H2030 LKB1 cells after treatment with vehicle, trametinib (0.1 µM) for 24 h or trametinib for 24 h followed by AMG 176 (1 µM) for 4 h. B Time course of BCL-XL S62 phosphorylation in isogenic H2030 and H358 cells by western blot after treatment with 0.1 µM trametinib + 1 µM AMG 176. C Experimental approach for expressing MCL-1 & BCL-XL phospho-site mutants while suppressing endogenous MCL-1 and BCL-XL. Interrogated phosphorylation sites are designated in yellow, phosphomimetic sites in red. D MCL-1 phospho-site mutants do not reduce sensitivity to MCL-1 inhibition (∆AUC). After induction of mutant MCL-1 (or WT control) and knockdown of endogenous MCL-1, H2030 EV cells were treated with trametinib in the absence or presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot is an independent biological replicate (N = 3). E BCL-XL S62A mutant decreases MCL-1 dependence. After induction of BCL-XL S62A (or WT control) and knockdown of endogenous BCL-XL, H2030 EV cells were treated with sotorasib or trametinib alone or in the presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot is an independent biological replicate (N = 6, ****p = 0.000001, unpaired-parametric t test, two-sided). H2030 EV cells expressing inducible WT or S62A mutant BCL-XL S62A (F) or H2030 LKB1 cells expressing inducible WT or BCL-XL S62E phosphomimetic (G) were treated with 0.1 µM trametinib or 0.1 µM trametinib in combination with 1 µM AMG 176 and cell number was quantified by live-cell imaging. Data are mean and S.E.M. of 3 technical replicates. V vehicle, T trametinib, A AMG 176, TA trametinib + AMG 176. Source data are provided as a Source Data file. Western blots and immunoprecipitation images are representative of at least 2 independent biological replicates.
Fig. 4 JNK phosphorylates BCL-XL to drive an MCL-1 dependent state. A Co-IP of BIM bound to MCL-1 in H2030 EV (empty vector) and H2030 LKB1 cells after treatment with vehicle, trametinib (0.1 µM) for 24 h or trametinib for 24 h followed by AMG 176 (1 µM) for 4 h. B Time course of BCL-XL S62 phosphorylation in isogenic H2030 and H358 cells by western blot after treatment with 0.1 µM trametinib + 1 µM AMG 176. C Experimental approach for expressing MCL-1 & BCL-XL phospho-site mutants while suppressing endogenous MCL-1 and BCL-XL. Interrogated phosphorylation sites are designated in yellow, phosphomimetic sites in red. D MCL-1 phospho-site mutants do not reduce sensitivity to MCL-1 inhibition (∆AUC). After induction of mutant MCL-1 (or WT control) and knockdown of endogenous MCL-1, H2030 EV cells were treated with trametinib in the absence or presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot is an independent biological replicate (N = 3). E BCL-XL S62A mutant decreases MCL-1 dependence. After induction of BCL-XL S62A (or WT control) and knockdown of endogenous BCL-XL, H2030 EV cells were treated with sotorasib or trametinib alone or in the presence of AMG 176 (1 µM) and viability was determined after 3 days. Each dot is an independent biological replicate (N = 6, ****p = 0.000001, unpaired-parametric t test, two-sided). H2030 EV cells expressing inducible WT or S62A mutant BCL-XL S62A (F) or H2030 LKB1 cells expressing inducible WT or BCL-XL S62E phosphomimetic (G) were treated with 0.1 µM trametinib or 0.1 µM trametinib in combination with 1 µM AMG 176 and cell number was quantified by live-cell imaging. Data are mean and S.E.M. of 3 technical replicates. V vehicle, T trametinib, A AMG 176, TA trametinib + AMG 176. Source data are provided as a Source Data file. Western blots and immunoprecipitation images are representative of at least 2 independent biological replicates.CC BY · PubMed Central
Fig. 5 JNK activation drives an MCL-1 dependent state by modulating BIM:BCL-XL interactions. A Scheme for approach to investigating BIM sequestration upon displacement from MCL-1. B Co-IP assessment of BIM bound to MCL-1 and BCL-XL in H2030 (LKB1-deficient) and SW1573 (LKB1 wild-type) cells after treatment with 0.1 µM trametinib for 24 h followed by 1 µM AMG 176 for 4 h. C Co-IP assessment of BIM bound to BCL-XL and MCL-1 in H2030 EV and LKB1 cells after treatment with 0.1 µM trametinib for 24 h followed by 1 µM AMG 176 for 4 h. D Co-IP assessment of BIM bound to BCL-XL and MCL-1 in H2030 EV (empty vector) with JNK knockdown after treatment with 0.1 µM trametinib for 24 h + 1 µM AMG 176 for 4 h. E Co-IP assessment of BIM bound to WT BCL-XL or BCL-XL mutants in H2030 EV (S62A) and H2030 LKB1 (S62E) cells after treatment with 0.1 µM trametinib for 24 h followed 1 µM AMG 176 for 4 h. HA-tag pull downs are specific for inducible constructs. F Quantification of Co-IP assessment of BIM bound to BCL-XL in H2030 and MGH1112 cells overexpressing BCL-XL WT or S62A mutants. Data are mean and S.E.M., each dot represents a biological replicate (N = 3-5, H2030: *p = 0.0433, MGH1112-1: *p = 0.0345, unpaired-parametric t test, 2-sided). G Effect of NUAK1/2 knockdown on BCL-XL S62 phosphorylation in response to treatment with 0.1 µM trametinib for 48 h (T) or trametinib for 48 h followed by 1 µM AMG 176 (TA) for 4 h. H Model depicting the mechanism by which LKB1 loss leads to an MCL-1-dependent state and sensitizes KRAS-mutant NSCLCs to combined KRAS or MEK + MCL-1 inhibition. Source data are provided as a Source Data file. Western blots and immunoprecipitation images are representative of at least 2 independent biological replicates.
Fig. 5 JNK activation drives an MCL-1 dependent state by modulating BIM:BCL-XL interactions. A Scheme for approach to investigating BIM sequestration upon displacement from MCL-1. B Co-IP assessment of BIM bound to MCL-1 and BCL-XL in H2030 (LKB1-deficient) and SW1573 (LKB1 wild-type) cells after treatment with 0.1 µM trametinib for 24 h followed by 1 µM AMG 176 for 4 h. C Co-IP assessment of BIM bound to BCL-XL and MCL-1 in H2030 EV and LKB1 cells after treatment with 0.1 µM trametinib for 24 h followed by 1 µM AMG 176 for 4 h. D Co-IP assessment of BIM bound to BCL-XL and MCL-1 in H2030 EV (empty vector) with JNK knockdown after treatment with 0.1 µM trametinib for 24 h + 1 µM AMG 176 for 4 h. E Co-IP assessment of BIM bound to WT BCL-XL or BCL-XL mutants in H2030 EV (S62A) and H2030 LKB1 (S62E) cells after treatment with 0.1 µM trametinib for 24 h followed 1 µM AMG 176 for 4 h. HA-tag pull downs are specific for inducible constructs. F Quantification of Co-IP assessment of BIM bound to BCL-XL in H2030 and MGH1112 cells overexpressing BCL-XL WT or S62A mutants. Data are mean and S.E.M., each dot represents a biological replicate (N = 3-5, H2030: *p = 0.0433, MGH1112-1: *p = 0.0345, unpaired-parametric t test, 2-sided). G Effect of NUAK1/2 knockdown on BCL-XL S62 phosphorylation in response to treatment with 0.1 µM trametinib for 48 h (T) or trametinib for 48 h followed by 1 µM AMG 176 (TA) for 4 h. H Model depicting the mechanism by which LKB1 loss leads to an MCL-1-dependent state and sensitizes KRAS-mutant NSCLCs to combined KRAS or MEK + MCL-1 inhibition. Source data are provided as a Source Data file. Western blots and immunoprecipitation images are representative of at least 2 independent biological replicates.CC BY · PubMed Central
Fig. 6 LKB1 loss in associated with MCL-dependence of KRASG12C-mutant NSCLC PDX tumors and patient tumor explants. A KRASG12C-mutant NSCLC tumor cells were collected for BH3 profiling and assessment of BIM:MCL-1 interactions after ex vivo treatment with sotorasib or trametinib. B Change in MCL-1 (MS1 10 + 30 µM peptide) and BCL-XL (HRK 10 + 100 µM peptide) dependent priming of patient tumor cells after ex vivo treatment with 0.1 µM trametinib or 1 µM sotorasib treatment. Data is normalized to Vehicle control and error bar presents S.E.M. (N = 3,6. *p = 0.0476, unpaired-nonparametric t test, 2-sided). C Co-IP assessment of BIM:MCL-1 interaction in tumor cells isolated from pleural fluid after ex vivo treatment with 0.1 µM trametinib (T) or 1 µM sotorasib (S) for 16 h. Data is representatives of 2 independent biological replicates. D Mice bearing KRASG12C-mutant NSCLC patient derived xenograft (PDX) tumors were treated with sotorasib (100 mg/kg) for 3 days and harvested for BH3 profiling. Data shown is the difference in MCL-1 dependent priming (MS1 peptide) of sotorasib treated tumors normalized to vehicle control, each dot represents an independent mouse tumor with error bar as S.E.M. (N = 3–7, ***p = 0.0002, 2-way ANOVA). E Mice bearing KRASG12C-mutant NSCLC PDX tumors (LKB1-loss: MGH1112-1, MGH1138-1, MGH1196-2; LKB1 WT: MGH1062-1, MGH1145-1, MGH10199-3) were treated with vehicle, sotorasib (100 mg/kg), AMG 176 (50 mg/kg) or sotorasib (100 mg/kg) + AMG 176 (50 mg/kg) daily. Data shown are mean and S.E.M. of N = 6–10 animals per arm, statistical difference between single agent and combination arms was determined using mixed-effects model, ****p = 0.00001, *p = 0.013, 2-way ANOVA). F Survival curves of PDX tumor-bearing mice: the progression free survival (PFS) metric was determined by time to 20% increase in tumor volume from baseline measurement (****p = 0.0001, **p = 0.0087, Log-rank Mantel-Cox test). Source data are provided as a Source Data file. A–D Created in BioRender. Li, C. (2025) https://BioRender.com/p50l332.
Fig. 6 LKB1 loss in associated with MCL-dependence of KRASG12C-mutant NSCLC PDX tumors and patient tumor explants. A KRASG12C-mutant NSCLC tumor cells were collected for BH3 profiling and assessment of BIM:MCL-1 interactions after ex vivo treatment with sotorasib or trametinib. B Change in MCL-1 (MS1 10 + 30 µM peptide) and BCL-XL (HRK 10 + 100 µM peptide) dependent priming of patient tumor cells after ex vivo treatment with 0.1 µM trametinib or 1 µM sotorasib treatment. Data is normalized to Vehicle control and error bar presents S.E.M. (N = 3,6. *p = 0.0476, unpaired-nonparametric t test, 2-sided). C Co-IP assessment of BIM:MCL-1 interaction in tumor cells isolated from pleural fluid after ex vivo treatment with 0.1 µM trametinib (T) or 1 µM sotorasib (S) for 16 h. Data is representatives of 2 independent biological replicates. D Mice bearing KRASG12C-mutant NSCLC patient derived xenograft (PDX) tumors were treated with sotorasib (100 mg/kg) for 3 days and harvested for BH3 profiling. Data shown is the difference in MCL-1 dependent priming (MS1 peptide) of sotorasib treated tumors normalized to vehicle control, each dot represents an independent mouse tumor with error bar as S.E.M. (N = 3–7, ***p = 0.0002, 2-way ANOVA). E Mice bearing KRASG12C-mutant NSCLC PDX tumors (LKB1-loss: MGH1112-1, MGH1138-1, MGH1196-2; LKB1 WT: MGH1062-1, MGH1145-1, MGH10199-3) were treated with vehicle, sotorasib (100 mg/kg), AMG 176 (50 mg/kg) or sotorasib (100 mg/kg) + AMG 176 (50 mg/kg) daily. Data shown are mean and S.E.M. of N = 6–10 animals per arm, statistical difference between single agent and combination arms was determined using mixed-effects model, ****p = 0.00001, *p = 0.013, 2-way ANOVA). F Survival curves of PDX tumor-bearing mice: the progression free survival (PFS) metric was determined by time to 20% increase in tumor volume from baseline measurement (****p = 0.0001, **p = 0.0087, Log-rank Mantel-Cox test). Source data are provided as a Source Data file. A–D Created in BioRender. Li, C. (2025) https://BioRender.com/p50l332.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 1 Not valid · 8 Not checked · 116 Own results and interpretations

71 more claims · 1 with their cited sources checked

Create a free account to see all 148 claims and to verify the 14 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 34
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 93 references

Cited by

See all 11

Metadata

Authors
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., Kelley, G., Hensley, E. M., Morris, R., Lazaro, R., Belmonte, B., Oh, A., Walcott, M., Nabel, C. S., Caenepeel, S., Saiki, A. Y., Rex, K., Lipford, J. R., Heist, R. S., Lin, J. J., Haas, W., Sarosiek, K., Hughes, P. E., & Hata, A. N.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • Medical University of South Carolina (US)
  • Amgen (United States) (US)
Corresponding author
Hata, Aaron N.
Venue
Nature Communications
Published
2025-05-02
Volume
16
Issue
1
Pages
4112-4112
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4410029176
Cited by
11
References
93
Citations by year
2026: 8 · 2025: 3
FWCI
3.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Association for Cancer Research (SU2C-AACR-DT17-15)
  • Conquer Cancer Foundation
  • Amgen
  • American Society of Clinical Oncology
  • Entertainment Industry Foundation
  • Massachusetts Institute of Technology
  • National Institutes of Health
  • Stand Up To Cancer (SU2CAACR- DT17-15)
  • Ludwig Center at Harvard
  • National Heart, Lung, and Blood Institute (T32HL007118)
  • National Cancer Institute (F32CA250231, P50CA265826)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
LKB1, STK11, KRAS-mutant lung cancer, JNK signaling, stress signaling, apoptosis, Bcl-xL, Mcl-1, MEK inhibition, KRAS-targeted therapy, mitochondrial apoptosis
MeSH terms
AMP-Activated Protein Kinase Kinases, Animals, Humans, Lung Neoplasms, Mutation, Phosphorylation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Apoptosis, Protein Serine-Threonine Kinases, MAP Kinase Signaling System, Cell Line, Tumor, bcl-X Protein, Mice, AMP-Activated Protein Kinases, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers. https://app.cochat.ai/papers/10.1038/s41467-025-58753-y
The paper
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., Kelley, G., Hensley, E. M., Morris, R., Lazaro, R., Belmonte, B., Oh, A., Walcott, M., Nabel, C. S., . . . Hata, A. N. (2025). LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers. Nature Communications. https://doi.org/10.1038/s41467-025-58753-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.